Contineum Therapeutics (CTNM) Return on Sales (2023 - 2024)
Contineum Therapeutics' (CTNM) quarterly Return on Sales came in at 0.01% in Q2 2024, down 1.0% year-on-year from 0.01% in Q3 2023, and down 174.64% quarter-over-quarter from 0.01% in Q2 2023.
Contineum Therapeutics (CTNM) Return on Sales (2023 - 2024) Analysis & Trends
Contineum Therapeutics' Return on Sales history runs 2 years deep, the most recent figure standing at 0.01% for Q2 2024.
- On a quarterly basis, Return on Sales fell 1.0% year-over-year to 0.01% in Q2 2024; TTM through Jun 2024 was 0.01%, a N/A change from a year earlier, with the FY2023 full-year figure at 0.0%, changed N/A from the prior year.
- Return on Sales eased to 0.01% in Q2 2024 per CTNM's latest filing, from 0.01% in the prior quarter.
- Across five years, Return on Sales topped out at 0.01% in Q2 2023 and bottomed at 0.01% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Contineum Therapeutics | 536.56 Mn | 536.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -0.01% |
| Jun 30, 2023 | 0.01% |